Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PI3K, AKT, and mTOR pathway inhibitors
20 evidence topics · 20 sources
Guideline recommendation: NCCN, PIK3CA, AKT1, or PTEN alterations
Guideline recommendation: ABC8, PI3K/AKT/mTOR pathway inhibitor class
“The EPIK-B5 trial confirmed that alpelisib + fulvestrant retains meaningful activity after CDK4/6i-based therapy in PIK3CA-mutated disease (median PFS improvement of 4.6 months; HR: 0.52), consolidating this combination as a valid option in the absence of contraindications [ 36 ].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management [ 39 ]. The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: ASCO 2021, alpelisib and everolimus
“Alpelisib in combination with ET should be offered to postmenopausal patients in combination with fulvestrant, and to male patients, with HR-positive, HER2-negative, PIK3CA-mutated, ABC, or MBC following prior ET including an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, everolimus may be an option in second or subsequent lines of endocrine-based therapy, although the clinical benefits in contemporary practice in patients treated with CDK4/6 inhibitors are not well defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are no data for the use of alpelisib after everolimus, or vice versa, to guide clinical recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capivasertib, CAPItello-291: progression-free survival
“Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capivasertib, CAPItello-291: biomarker-negative subgroup and overall survival
Comparator regulatory information: alpelisib
Alpelisib, SOLAR-1: progression-free survival and toxicity
“In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 months was 11.0 months (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 months (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpelisib, SOLAR-1: overall survival
“In the PIK3CA-mutated cohort (n = 341), median OS [95% confidence interval (CI)] was 39.3 months (34.1-44.9) for alpelisib-fulvestrant and 31.4 months (26.8-41.3) for placebo-fulvestrant [hazard ratio (HR) = 0.86 (95% CI, 0.64-1.15; P = 0.15)]. OS results did not cross the prespecified efficacy boundary.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpelisib after a CDK4/6 inhibitor: BYLieve
Comparator regulatory information: inavolisib (first-line, endocrine-resistant disease)
Inavolisib, INAVO120: progression-free survival
“The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inavolisib, INAVO120: overall survival
“After a median follow-up of 34.2 months in the inavolisib group and 32.3 months in the placebo group, the median overall survival was 34.0 months (95% confidence interval [CI], 28.4 to 44.8) with inavolisib and 27.0 months (95% CI, 22.8 to 38.7) with placebo (hazard ratio for death, 0.67; 95% CI, 0.48 to 0.94; P = 0.02 [prespecified boundary for statistical significance, P<0.0469]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to discontinuation of inavolisib in 6.8% of patients and discontinuation of placebo in 0.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inavolisib: NCCN limitation on sequencing
Comparator regulatory information: gedatolisib
Gedatolisib, VIKTORIA-1: safety
“Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: everolimus
Everolimus, BOLERO-2: progression-free survival and toxicity
“The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was 10.6 months and 4.1 months, respectively, according to central assessment (hazard ratio, 0.36; 95% CI, 0.27 to 0.47; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Everolimus, BOLERO-2: overall survival
“Median OS in patients receiving EVE + EXE was 31.0 months [95% confidence interval (CI) 28.0–34.6 months] compared with 26.6 months (95% CI 22.6–33.1 months) in patients receiving PBO + EXE (hazard ratio = 0.89; 95% CI 0.73–1.10; log-rank P = 0.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote